A RECENT study has found that haemorrhages are far more frequent in cancer patients than previously believed, posing a serious threat to their prognosis and overall survival. The research was conducted by MedUni Vienna and highlights the urgent need for increased clinical focus on bleeding risks in cancer patients.
The study followed 791 cancer patients over 19 months and revealed a high incidence of both mild and severe bleeding events, known as “major bleeds.” Even patients not undergoing anticoagulation therapy, which is commonly used to prevent blood clots in cancer patients, were found to be at substantial risk. Low levels of albumin and haemoglobin, routinely checked markers in medical assessments, were identified as key indicators of higher bleeding risk.
Notably, the study uncovered a previously unrecognised form of bleeding termed “tumour bleeding,” which originates directly from the tumour and accounted for nearly a third of the bleeding events. Patients with head and neck tumours were particularly susceptible.
The findings show that haemorrhages in patients with cancer are associated with a poorer prognosis and higher mortality rates. The findings call for more research and clinical attention to address bleeding risks in cancer care, which could significantly impact patient outcomes and treatment strategies.
Aleksandra Zurowska, EMJ
Reference
Englisch C et al. Bleeding events in patients with cancer: incidence, risk factors, and impact on prognosis in a prospective cohort study. Blood. 2024;DOI:10.1182/blood.2024025362.
